Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GE Vernova Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while GE Vernova Inc trades at $1,075.67 (market cap $293.33B). The key difference: GE Vernova Inc is far larger — about 7.4× Alnylam Pharmaceuticals, Inc.'s market cap, and GE Vernova Inc pays a 0.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GEV | |
|---|---|---|
Market Cap | $39.89B | $293.33B |
Sector | Health | Technology |
52-Week High | $491.22 | $1.17K |
52-Week Low | $278.09 | $539.16 |
Enterprise Value | $38.15B | $285.96B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GE Vernova (GEV) trades at $1,091.57, up 1.52% with strong analyst support (75% buy ratings) and a consensus price target of $1,230. The stock shows bullish technical momentum with recent earnings beats and robust profitability metrics including 23.81% net income margin and 83.23% ROE. Recent news highlights the company's strategic positioning in AI power infrastructure and nuclear energy expansion.
Outlook remains positive with projected revenue growth to $39.4B and net profit doubling to $9.4B in 2026. Key risks include high valuation multiples (P/E 31.9, EV/EBITDA 113.7) and execution challenges in scaling nuclear operations. The stock offers exposure to AI-driven power demand but faces volatility from energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
